APSR2026-942

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-017
P72
https://storage.unitedwebnetwork.com/files/1288/c03b4f4cc8290506a44b4e69f8b68f9a.pptx
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1288/e9c3df124b65144504b7c561a10d604a.pdf
Format: PDF Only
06. Tuberculosis
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Roman Ladyu - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Anastasia Gaida * National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Ruslan Khachetlov - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Anna Abramchenko - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Mariya Romanova - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Denis Churkin - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Irina Burmistrova - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Anastasia Samoylova - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
-
-
-
-
-
-
-
Presenting Author Details
Anastasia
Gaida
nsovca@yandex.ru
+7+7+79992991986
31-40
 
Original Research
Clofazimine accelerates sputum conversion in drug-resistant tuberculosis
Maximum 25 words
Abstract Content
Improving early bacteriological response remains a priority in drug-resistant tuberculosis. This study aimed to evaluate whether adding clofazimine to individualized chemotherapy shortens the time to sputum conversion in patients with multidrug-resistant, pre-extensively drug-resistant, and extensively drug-resistant tuberculosis.
We analyzed 150 patients with pulmonary multidrug-resistant, pre-extensively drug-resistant, or extensively drug-resistant tuberculosis. The clofazimine group included 75 patients who received clofazimine 100 mg/day in addition to four anti-tuberculosis drugs selected according to drug susceptibility testing. The control group included 75 patients treated with individualized regimens without clofazimine. Regimens included 4-5 anti-tuberculosis drugs. Groups were comparable by sex, age, resistance profile, and comorbidities. Bacteriological response was assessed monthly for 24 weeks by smear microscopy and culture.
At month 1, sputum conversion by all methods was achieved in 81.3% of patients in the clofazimine group versus 42.7% in the control group (p<0.001). The difference persisted at month 2: 83.8% versus 56.0% (p<0.001), and month 3: 87.7% versus 65.3% (p=0.0018). From month 4, between-group differences were no longer statistically significant. Mean time to sputum conversion was shorter with clofazimine: 35.55 versus 69.79 days by microscopy and 59.68 versus 73.32 days by culture.
Adding clofazimine to individualized treatment was associated with faster sputum conversion and a higher frequency of early bacteriological response during the first three months of treatment in patients with drug-resistant tuberculosis.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Tuberculosis, Clofazimine, Sputum conversion
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflict of interest
235